INM InMed Pharma: רווח נקי למניה (EPS TTM)

The fundamental TTM net income per share metric highlights the impact of strict FDA oversight and the biosynthesis patent protection of InMed Pharmaceuticals (INM), where the -3.10 level serves as a critical benchmark. InMed Pharmaceuticals is implementing automated bacterial reactors to eliminate human error while simultaneously developing the Integram platform to create safe medications for skin and eye pathologies.

To minimize investment risks, it is necessary to evaluate the issuer's actual efficiency in capital generation. This metric is calculated as the ratio of total net income over the last four quarters to the total number of shares outstanding. By analyzing the TTM earnings per share, an investor determines the fundamental value of the business during periods of price stagnation. This trend reflects the financial stability of InMed Pharmaceuticals (INM). The eco-friendly biosynthesis of compounds reduces operating expenses, directly impacting the final profitability of each share.